AKT1 and neoplasm: In summary, the present study identified TIMP-1 overexpression in chemoresistant TNBC cell lines and tumor samples and demonstrated that knockdown of its expression reverses cell resistance to both cisplatin and doxorubicin, thereby inducing cell death, possibly through inhibition of the AKT pathway.